Rare disease research is chronically underfunded relative to its clinical burden — by definition, each individual condition affects too few patients to attract the commercial R&D investment that common diseases do, even though rare diseases collectively affect a meaningful share of the population. A compute-credit grant targeted specifically at this space is a more direct intervention than broad life-sciences funding, and worth flagging to any genetics or bioinformatics researchers in your network who might qualify.